Skip to content
Cancer — PARP inhibitorsATC L01XK01

Olaparib

Prescription onlyWHO essential medicine

PARP inhibitor tablet for BRCA-mutated ovarian, breast, prostate and pancreatic cancers.

Starts working
Depends on the cancer and regimen
Half-life
About 15 hours
In use since
—
Pregnancy
Usually avoided

Overview

Olaparib prevents cancer cells repairing DNA damage, which is especially lethal in tumours with BRCA mutations. Anaemia and nausea are common.

How it works

Stops cancer cells repairing their DNA.

Olaparib belongs to the PARP inhibitors. How PARP inhibitors work: block a DNA repair enzyme, which is lethal to cells already lacking BRCA repair.

Uses

  • BRCA-mutated ovarian cancer
  • BRCA-mutated breast cancer
  • Prostate cancer (HRR-mutated)
  • Pancreatic cancer

Available as: tablet.

Typical dose

Adults
Dosed by your cancer team according to the treatment protocol.
Good to know
Doses depend on body size, blood counts and the regimen.

Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.

Side effects

Common

Often mild and may settle with time

  • Nausea
  • Tiredness
  • Anaemia
  • Vomiting
  • Loss of appetite

Serious — get medical help

Uncommon, but need prompt attention

  • Myelodysplastic syndrome or leukaemia (rare)
  • Lung inflammation
  • Blood clots

Warnings

  • Avoid grapefruit juice

Who should avoid it

  • Pregnancy
  • Severe kidney impairment

Interactions

  • Ketoconazole, clarithromycin, grapefruit — raised levels
  • Rifampicin, St John's wort — lower levels

Other medicines in the atlas that need care with Olaparib, grouped by the reason:

Added bone marrow suppressionModerateWith Azathioprine, Bortezomib, Capecitabine, Carbimazole, Carboplatin and 26 more
Reduced effectModerateWith Carbamazepine, Efavirenz, Enzalutamide, Griseofulvin, Modafinil and 5 more

Enzyme induction lowers levels of this medicine, which may stop it working.

What's usually done: Monitor effect; dose changes or alternatives may be needed. The effect lasts weeks after stopping the inducer.

Raised drug levelsModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more

Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.

What's usually done: A dose reduction, alternative or extra monitoring may be needed.

Bleeding risk with low plateletsModerateWith Aspirin, Cilostazol, Clopidogrel, Dipyridamole, Prasugrel and 1 more

Antiplatelet treatment adds to bleeding risk when another medicine suppresses platelet production.

What's usually done: Monitor blood counts and report unusual bruising or bleeding.

Check Olaparib against your own medicines

Using it safely

Alcohol
Best to limit. Alcohol can add to nausea.
Food and drink
With or without food; avoid grapefruit.
If you miss a dose
Skip and take the next dose as normal.
Stopping it
Only on advice of your cancer team.
Driving
Tiredness or dizziness may affect driving.
Tests and checks
Blood counts monthly; Kidney function
If too much is taken
Seek medical advice.
Storage
Room temperature.
Legal status
United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HAustralia: Prescription only (Schedule 4)

Pregnancy and breastfeeding

Pregnancy

Usually avoided

Avoid.

Breastfeeding

Usually avoided

Avoid.

Special groups

Kidney disease
Dose may need adjusting; your team will advise.
Liver disease
Dose may need adjusting; your team will advise.
Older adults
Older adults may be more sensitive to side effects.

Brand names

United States
Lynparza
United Kingdom
Lynparza
India
Lynparza, Olaparib (generic)
Australia
Lynparza

Examples only; many generic versions exist. The same brand name can mean different products in different countries.

Common questions

Do I need a prescription for Olaparib?

Yes — Olaparib is prescription-only in most countries.

Can I take Olaparib during pregnancy?

Usually avoided. Avoid. Always check with a doctor or midwife.

How quickly does Olaparib work?

Depends on the cancer and regimen.

Sources and official information

Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.